If you or someone you know is in a medical emergency, call 911. The 988 Suicide and Crisis Lifeline is available 24/7 by call or text.
7-OH is not kratom leaf. 7-hydroxymitragynine makes up less than two percent of the alkaloid content of the raw kratom plant, and the Drug Enforcement Administration's proposed rule would place any product carrying more than 0.050 percent of it by weight into Schedule I, which is the line the tablets and shots sold as "7-OH" sit on the far side of. The label on the package often says kratom. The pharmacology inside it does not match the plant, and that gap is the reason men who moved from leaf to tablets find they cannot put the tablets down.
7-OH and kratom leaf are not the same product
Kratom leaf carries mitragynine as its major alkaloid and 7-OH only in trace amounts. Products sold as 7-OH are concentrated or synthesized to deliver a dose the leaf never produces, and the DEA describes their pharmacological profile as similar to Schedule II opioids such as morphine. Read the leaf section if he is chewing or brewing plant material, and the 7-OH section if he is taking a tablet, shot, or gummy from a counter.
7-OH and kratom leaf side by side
Six differences that matter clinically, drawn from the DEA's July 2026 notice of intent and the poison centre data published inside it.
| Question | Kratom leaf | 7-OH products |
|---|---|---|
| Share of the alkaloid content | Mitragynine is the major alkaloid. 7-OH is a minor one, under two percent of total alkaloid content or trace | Concentrated or synthesized so 7-OH is the active ingredient, not a trace component |
| How 7-OH reaches the body | Mostly made inside the body, as an oxidized metabolite of mitragynine | Swallowed directly, at a dose the plant does not produce |
| Comparator the DEA uses | Described as the plant matrix, with mitragynine and 7-OH together responsible for its effects | Pharmacological profile similar to Schedule II opioids such as morphine, and abuse potential similar to heroin and fentanyl |
| Product form and dosing pattern | Leaf and leaf powder | Tablets, gummies, shots, capsules, powders, and sprays, with a short-lived effect that drives frequent redosing |
| Federal legal status, September 2026 | Not federally scheduled | Threshold rule proposed, not yet issued, at more than 0.050 percent by weight. Three related synthetic compounds entered Schedule I on August 26, 2026 |
| Poison centre outcomes | Reported separately, and not the subject of this dataset | 165 exposure cases from January 1 to July 31, 2025. Of those involving 7-OH alone, 35 percent had serious health problems and 67 percent were treated at a healthcare facility |
Four things to hold onto
- The molecule is the same. The dose is not. The DEA states that synthetic and naturally occurring 7-hydroxymitragynine are chemically identical, so what separates a leaf from a tablet is how much arrives and how fast, never a difference in chemistry.
- Under two percent versus 0.050 percent. 7-OH is under two percent of the plant's total alkaloid content, and the DEA's proposed threshold sits at more than 0.050 percent by weight of the finished product.
- "Plant based" and "sold at a counter" are not safety statements. Poison centres logged 165 exposure cases in seven months of 2025, and 67 percent of single-substance cases were treated at a healthcare facility.
- Stopping is a clinical question, not a willpower question. 7-OH acts on the same mu-opioid receptors as morphine, and withdrawal follows the opioid pattern.
What kratom leaf is
Kratom is a tree. Mitragyna speciosa is native to Southeast Asia, and its leaves have been chewed and brewed there for generations. The Drug Enforcement Administration's July 2026 notice of intent describes its chemistry plainly: among the plant's many alkaloids, two are primarily responsible for the psychoactive effects, mitragynine as the major one and 7-hydroxymitragynine as the minor one.
What the body does with mitragynine
The 2019 paper by Kruegel and colleagues in ACS Central Science established the relationship that most of the confusion turns on. 7-OH is an active metabolite of mitragynine and a key mediator of its effects, which means a person who consumes leaf takes in mitragynine and the body converts a portion of it to 7-OH afterward.
That conversion is gradual and partial, and it is capped by how much mitragynine was consumed. Swallowing 7-OH directly skips those limits. The body never gets to meter the dose.
What 7-OH is
7-hydroxymitragynine is a real compound found in the kratom plant. The DEA states that in its natural botanical form it makes up less than two percent of total alkaloid content, or occurs in trace amounts.
A minor alkaloid, a metabolite, and a synthesis route
The same notice records that 7-OH can be synthesized from mitragynine through a one-step chemical reaction. So it exists three ways: as a trace component of the plant, as something the body makes from mitragynine, and as a compound produced in a lab.
What matters clinically is what the DEA says next. The chemical structures of synthetic and naturally occurring 7-hydroxymitragynine are identical, so receptor affinity and mechanism of action are the same regardless of source. No version of this molecule is gentler for having come from a plant.
What "concentrated" means on a label
Products marketed as 7-OH arrive as tablets, gummies, shots, capsules, powders, and sprays, and the DEA notes they are sometimes labelled as natural M. speciosa extracts. That labelling is where the false equivalence starts. A man reading "kratom extract" reasonably assumes he is buying a stronger version of a leaf product, when the concentration has moved the minor alkaloid into the driver's seat. The Food and Drug Administration titled its 2026 consumer notice on these products Hiding in Plain Sight, which is a fair description of how they sit on a shelf beside leaf powder.
How they differ on potency and receptor activity
The DEA's notice places 7-OH's pharmacological profile alongside Schedule II opioids such as morphine, and states that it has an abuse potential similar to Schedule I and II opioids including heroin and fentanyl. Those comparisons are about 7-OH. They are not made about kratom leaf.
The FDA's 2025 scientific assessment, which carries the subtitle An Assessment of the Scientific Data and Toxicological Concerns Around an Emerging Opioid Threat, found in preclinical work that 7-OH depresses breathing at more than three times the potency of morphine. Respiratory depression is the mechanism behind an opioid overdose, so a potency multiple on that specific effect is not an abstract number.
A case series summarised in the DEA notice includes a 29-year-old man whose cardiopulmonary arrest after 7-OH exposure was reversed with naloxone, a drug that works on opioid receptors. That it worked confirms what 7-OH is doing in the body.
How they differ on how fast dependence forms
The DEA notice records a consistent pattern in user reports analysed by clinical educators between 2024 and early 2025: people transition from traditional kratom leaf to 7-OH tablets. The same reports describe the effect as short-lived, with a reported urge to redose frequently.
Short duration plus frequent redosing plus rising tolerance is the standard route to physical dependence with any opioid, and it runs faster when there is no prescriber setting an interval. One case report in the DEA notice describes a 38-year-old man who required inpatient buprenorphine stabilization for high-dose 7-OH withdrawal.
The mechanism behind that speed is its own subject. For the fuller explanation, see why dependence on 7-OH forms so quickly.
How they differ on overdose and poison centre outcomes
The numbers are small but the outcomes are not. United States poison centres logged 165 exposure cases involving 7-OH between January 1 and July 31, 2025, published inside the DEA notice. Among cases reporting 7-OH alone, 35 percent resulted in serious health problems and 67 percent of the people involved were treated at a healthcare facility.
The symptoms poison centres recorded fall into four groups: gastrointestinal, neurological including seizure, cardiovascular including a fast heart rate and high blood pressure, and respiratory.
A second problem sits underneath the first. The DEA states that these products come from sources where the identity, purity, and concentration of the active ingredient are often unknown and inconsistent. Two tablets from the same shelf may not carry the same dose. Tolerance stops being a reliable guide.
How they differ on legal status
As of September 10, 2026 neither kratom leaf nor 7-OH is federally scheduled, though the second half of that sentence is in the middle of changing.
On July 6, 2026 the DEA published a notice of intent, Docket DEA-1570, to temporarily place 7-hydroxymitragynine above a specified threshold into Schedule I. The threshold is more than 0.050 percent by weight. On August 26, 2026 a separate final rule placed three related synthetic compounds, mitragynine pseudoindoxyl, MGM-15, and MGM-16, into Schedule I, and on the same day the comment period on the 7-OH proposal was extended. The 7-OH threshold order had not been issued when this was written.
Arizona law moves on its own schedule. For the current position on both, see where federal and Arizona law currently stand.
None of this is a safety rating. A product being purchasable this month says something about rulemaking timelines. It says nothing about what the compound does to a body, or how hard it is to stop.
What this means if he is using either one
The practical question is rarely which substance is worse. It is whether what he is taking has become something he cannot stop, and that does not depend on which shelf it came from.
Signs worth acting on
Taking it through the day to feel level rather than to feel anything. A dose that has climbed steadily over weeks. Planning the day around when the next one is due. Trying to stop and getting as far as the second or third day before the symptoms win.
That last pattern is information rather than a character flaw. Opioid withdrawal peaks early, and an unsupervised attempt tends to end exactly where the symptoms are worst.
Where treatment fits
Guiding Road Recovery Center is a men-only program in the Phoenix metro for men working through substance use and co-occurring mental health conditions. It offers residential treatment, partial hospitalization, and intensive outpatient, and is Joint Commission accredited for behavioral health care.
Guiding Road does not provide detox on site. Where withdrawal needs medical supervision first, the admissions team coordinates that with a medical partner and holds his place. The two steps connect rather than leaving a gap.
Treatment for opioid use disorder takes several forms. Medication-assisted treatment, including FDA-approved medications, is one approach with strong clinical evidence. Abstinence-based, 12-step-immersive programs like Guiding Road are another. The right fit depends on the individual and is something the admissions team can help think through.
Recovery is possible and the work is real. What it looks like depends on the person. If the product in question is a concentrated one, the program specifics are on the page for 7-OH addiction treatment in Phoenix.
Common questions
Is 7-OH the same thing as kratom?
No. Kratom leaf carries mitragynine as its major alkaloid, and 7-hydroxymitragynine makes up less than two percent of total alkaloid content or occurs in trace amounts. Products sold as 7-OH are concentrated or synthesized so that the minor alkaloid becomes the active ingredient.
Is 7-OH in kratom leaf at all?
Yes, in trace amounts. Most of the 7-OH a person is exposed to from leaf is made inside the body, as an oxidized metabolite of mitragynine, rather than consumed directly.
Is synthetic 7-OH different from the kind in the plant?
Not chemically. The DEA states that the structures of synthetic and naturally occurring 7-hydroxymitragynine are identical, so receptor affinity and mechanism of action are the same regardless of source. What differs between a leaf and a tablet is the dose and how quickly it arrives.
Is 7-OH an opioid?
It acts on mu-opioid receptors. The DEA describes its pharmacological profile as similar to Schedule II opioids such as morphine, and a documented case of cardiopulmonary arrest after 7-OH exposure was reversed with naloxone, which works on opioid receptors.
Is 7-OH stronger than kratom leaf?
The comparison the federal record makes is with morphine, not with leaf. The FDA's 2025 assessment found in preclinical work that 7-OH depresses breathing at more than three times the potency of morphine.
Is 7-OH legal?
As of September 10, 2026 it is not federally scheduled, and that is being changed. The DEA published a notice of intent on July 6, 2026 to place 7-OH above 0.050 percent by weight into Schedule I, and the comment period was extended on August 26, 2026. Three related synthetic compounds entered Schedule I on that same date. State law varies.
What happens to the body when someone stops?
Withdrawal follows the opioid pattern. Poison centres recorded gastrointestinal, neurological, cardiovascular, and respiratory symptoms in 7-OH cases, including seizure, a fast heart rate, and high blood pressure. Stopping alone is not always safe, and it becomes a medical question when alcohol, benzodiazepines, or other opioids are also involved.
Does Guiding Road provide detox?
No. Guiding Road does not provide detox on site. The admissions team coordinates detox with medical partners and holds a place in the men's program in Phoenix for when he is medically stable.
Sources
- Drug Enforcement Administration. (2026). Schedules of Controlled Substance: Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I. Docket No. DEA-1570. Federal Register, July 6, 2026. federalregister.gov
- Drug Enforcement Administration. (2026). Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I. Docket No. DEA-1644. Federal Register, August 26, 2026. federalregister.gov
- U.S. Food and Drug Administration. (2025). 7-Hydroxymitragynine (7-OH): An Assessment of the Scientific Data and Toxicological Concerns Around an Emerging Opioid Threat. fda.gov
- U.S. Food and Drug Administration. (2026). Hiding in Plain Sight: 7-OH Products. fda.gov
- America's Poison Centers. (2025). Health Advisory: Serious Illnesses Associated with 7-OH Use. poisoncenters.org
- Kruegel, A. C., et al. (2019). 7-Hydroxymitragynine Is an Active Metabolite of Mitragynine and a Key Mediator of Its Analgesic Effects. ACS Central Science. pubs.acs.org
- Substance Abuse and Mental Health Services Administration. National Helpline, 1-800-662-4357. samhsa.gov
Get Help at Guiding Road
If he has tried to stop and keeps getting stuck in the first few days, that is a withdrawal problem with a clinical answer. Guiding Road's admissions team can talk through what he is taking, what stopping would involve, and what the next step looks like for him.
Clinically reviewed by
Bobby Boykin, MS, LASAC, CRS
Executive Director, Guiding Road Recovery Center
Clinical content on this page, including the receptor and potency descriptions and the withdrawal symptom groups, is reviewed by Guiding Road's Executive Director.